High Stable Hydrophilic Ointment RS-800

In hospital pharmacy compounding operations governed by USP <795> Pharmaceutical Compounding—Nonsterile Preparations, RS-800 High Stable Hydrophilic Ointment serves as the pre-manufactured base for extemporaneous topical prescriptions. The base is incorporated at 70–95 wt% of the final compounded mass, with the remaining fraction consisting of the active pharmaceutical ingredient geometrically diluted in a suitable levigating agent such as propylene glycol or light mineral oil at 0.5–3 wt% before incorporation. For a 2% menthol preparation, 98 g of RS-800 is combined with 2 g of micronized menthol that has been pre-wetted with 0.5 g of propylene glycol. Simple solutions are mixed on an ointment slab using a stainless-steel spatula in three stages of geometric dilution; suspensions containing particles above 50 μm are passed through a three-roll ointment mill with roller gaps set to 25–50 μm and a first-pass speed of 50–100 rpm to reduce agglomerates while preserving the lamellar network of the hydrophilic ointment. Automated compounding devices operating at 1,200–2,500 rpm for 30–180 s are used when batch sizes exceed 200 g; these devices introduce shear at a level that can lower apparent viscosity by 15–25% as measured by rotational viscometry per Ph. Eur. 2.2.10 or ASTM D2196-20, and shear recovery must be confirmed before packaging. The compounded product is filled into 30–100 mL airless pump bottles, polypropylene ointment jars, or aluminum tubes with internal epoxy phenolic linings; multiple-dose containers require antimicrobial effectiveness testing per USP <51>, and microbial enumeration per USP <61> is used as a release specification for batches exceeding 100 units. The default beyond-use date for water-containing topical semisolids stored at controlled room temperature is 30 days per USP <795>; refrigerated storage at 2–8 °C may extend the BUD only when configured with a stability-specific protocol and antimicrobial effectiveness testing per USP <51> that demonstrates no less than 1.0 log reduction of Staphylococcus aureus at 14 days and no less than 1.0 log reduction of Pseudomonas aeruginosa at 14 days. Terminal finished product types include extemporaneously compounded corticosteroid ointments, menthol and camphor rubs, lidocaine creams at 0.5–5 wt% API loading, and unit-dose syringes for institutional distribution. Batches prepared in registered outsourcing facilities under 21 CFR Part 210/211 must additionally meet USP <3> Topical and Transdermal Drug Products—Product Quality Tests for particle size, rheology, and in vitro release, with acceptance criteria defined per the approved compounding monograph. One process conflict observed on production-scale lines involves incorporation of high-ionic-strength API solutions such as 1–5 M sodium chloride or magnesium sulfate; direct addition without geometric dilution can collapse the emulsified phase and produce visible syneresis within 24–48 h at 40 °C. The operational boundary is therefore set at a maximum total electrolyte content of 0.3 wt% in the water phase of the compounded preparation, and any formulation exceeding this threshold must be reworked with a pre-emulsification step or replaced with a nonionic emulsification system. Published data for RS-800-specific shelf-life under these high-electrolyte configurations is limited; stability batches should be placed on ICH Q1A(R2) accelerated conditions at 40 °C ± 2 °C / 75% RH ± 5% RH for 6 months before assigning a commercial BUD.

Dermatological Prescription Cream Vehicles and Carbomer Interaction Thresholds

Prescription dermatological cream manufacture using RS-800 as the primary hydrophilic vehicle requires control of carbomer-based thickener interaction, because neutralized polyacrylic acid networks lose yield stress when the pre-manufactured ointment base is post-added at elevated shear. In a standard aqueous cream formulation, RS-800 is added at 55–85 wt% to a pre-neutralized carbomer phase, with 10–25 wt% purified water, 0.4–1.2 wt% Carbopol 980 NF, 0.2–0.6 wt% triethanolamine, and 1–5 wt% medium-chain triglycerides as the occlusive modifier. The relevant standard for the finished cream includes USP <3> product quality testing, USP <1724> semisolid drug product performance testing, and USP <51> antimicrobial effectiveness for preserved formulations in 100 g or larger multi-dose containers. Viscosity is determined at 25 °C ± 0.5 °C using a rotational viscometer with a T-bar spindle at 5 rpm per Ph. Eur. 2.2.10 or ASTM D2196-20; yield stress is obtained from shear stress ramp data over 0.01–100 s⁻¹ and should remain in the range 25–120 Pa to allow tube extrusion while preventing phase separation. The manufacturing line in question is a 100 L vacuum emulsifying kettle equipped with a counter-rotating anchor stirrer (15–30 rpm) and a rotor-stator homogenizer with a 5.5 kW drive operating at 2,500–3,500 rpm. The carbomer is hydrated for 45–60 min at 25 °C under vacuum of -0.08 MPa; triethanolamine is then added to reach pH 5.0–6.5, and the RS-800 base is incorporated at 35–40 °C over 15–20 min with the homogenizer running at 3,000 rpm. Homogenization beyond 10 min at this shear level reduces apparent viscosity by 18–30% because the lamellar gel structure is mechanically disrupted; an in-process viscosity check per ASTM D2196-20 is therefore performed after 5 min and again after 10 min, with the batch rejected if viscosity falls below 40,000 mPa·s unless RS-800-specific verification data confirms an alternative acceptance criterion. Deaeration at -0.09 MPa for 20 min follows the homogenization step, after which the cream is transferred through a 200 μm in-line filter to a storage vessel held at 25 °C. Finished product types from this process include 1% hydrocortisone cream, 0.1% triamcinolone acetonide ointment, 2% ketoconazole cream, and 5% urea emollient preparations. One threshold risk is the addition of RS-800 to a carbomer phase that is still below pH 4.5; the acidic conditions can protonate the emulsifier interface in RS-800 and produce a grainy precipitate that is not fully reversible by subsequent neutralization. Another operational incompatibility is observed with amine-based active ingredients such as 0.5–5 wt% lidocaine; pre-neutralization with triethanolamine before adding the base can produce an oily exudate on the cream surface after 72 h at 40 °C. Published data for RS-800-specific interaction thresholds with all amine actives is limited; compatibility screening should be performed in 50 g pilot batches using USP <1724> in vitro release testing before scale-up.

Because mastitis prevention in dairy herds requires a water-miscible base that accepts zinc oxide and lanolin without phase separation, RS-800 High Stable Hydrophilic Ointment is compounded into topical udder balms and wound salves for dairy and equine practice under EU Regulation (EU) 2019/6 for veterinary medicinal products and 21 CFR Part 530 extralabel drug use provisions. The base is incorporated at 50–75 wt% in a formulation that also includes 8–15 wt% zinc oxide USP, 3–8 wt% cod liver oil, 2–5 wt% lanolin anhydrous, and 0.3–1.0 wt% benzyl alcohol as a preservative. The production process uses a jacketed 50 L planetary mixer with a paddle speed of 20–40 rpm; the lipophilic fraction of lanolin and cod liver oil is melted at 65–70 °C, then cooled to 45 °C before the RS-800 base is folded in using three separate additions of 10 min each to avoid entrained air. Zinc oxide is pre-dispersed in 2–3 parts of the melted cod liver oil and passed through a 150 μm sieve to eliminate agglomerates; the final mixture is deaerated under -0.08 MPa for 15 min and filled into 250 mL polypropylene jars or 20 mL HDPE tubes. Terminal finished product types include mastitis prevention udder salves applied post-milking, wound salves for equine pastern dermatitis, and hoof conditioners containing 3–5 wt% sulfur. Compliance for these preparations in the EU requires a veterinary medicinal product marketing authorization under Regulation (EU) 2019/6 unless compounded under an extemporaneous veterinary prescription; in the United States, the compounded preparation falls under 21 CFR Part 530 and the Animal Medicinal Drug Use Clarification Act (AMDUCA). Microbiological quality is assessed per USP <61> with limits of ≤10² CFU/g total aerobic microbial count and ≤10¹ CFU/g combined yeast and mold; preserved multi-dose containers require USP <51> antimicrobial effectiveness. One incompatibility arises when the RS-800-containing udder salve is applied to teats that have been pre-dipped with iodine-based teat disinfectants; residual hypochlorous or iodophor species can oxidize the emulsifier system in RS-800, causing yellowing of the ointment surface and a drop in pH below 4.0 within 48 h. The operational boundary specifies a minimum 30 min interval between application of iodine-based pre-dip and application of the RS-800 salve, with no mixing in the same container. Published data for RS-800-specific oxidation kinetics in the presence of iodophor residues is limited; a formal compatibility study per ICH Q1A(R2) at 40 °C ± 2 °C / 75% RH ± 5% RH for 3 months is recommended before commercial distribution.

How Does RS-800 Perform in Occlusive Wound Care Matrices?

Occlusive wound care ointments formulated with RS-800 as the continuous aqueous phase introduce a trade-off between moisture retention at the wound bed and transepidermal water loss restriction that must be quantified by ASTM E96/E96M-22 desiccant method before selecting the final base fraction. RS-800 is used at 55–90 wt% in these matrices, combined with 5–15 wt% white petrolatum USP, 1–5 wt% allantoin, 0.5–2 wt% vitamin E acetate, and 0.2–0.5 wt% chlorhexidine gluconate when a topical antiseptic claim is permitted. The completed ointment is tested for in vitro water vapor transmission rate (WVTR) per ASTM E96/E96M-22 on a 100 cm² sample drawn to a thickness of 300 μm using a Bird applicator; for partial-occlusion wound care, the measured WVTR should fall between 250–500 g/m²/24 h at 38 °C ± 0.5 °C and 50% RH ± 2% RH. Biological evaluation per ISO 10993-1:2018 is required when the ointment is classified as a medical device under 21 CFR Part 878.4020 or the EU Medical Device Regulation (EU) 2017/745; cytotoxicity, sensitization, and irritation endpoints must be assessed on the finished formulation, not the base alone. The production process for sterile or low-bioburden wound care ointments uses an ISO Class 5 cleanroom environment per ISO 14644-1, with mixing performed in a 20 L stainless-steel vessel equipped with a radial-blade impeller at 10–25 rpm to maintain the lamellar phase; the mixture is not passed through a high-shear homogenizer because the resulting increase in temperature above 40 °C can destabilize chlorhexidine and reduce antimicrobial activity. Filling into 15 g or 30 g aluminum tubes with internal polyurethane lacquer and membrane-sealed orifices is conducted under laminar flow with continuous particle monitoring at the 0.5 μm and 5 μm thresholds per ISO 14644-1. Terminal finished product types include post-cautery balms, diabetic foot ulcer adjunct ointments, skin protectant pastes with 10–20 wt% zinc oxide, and radiation dermatitis emollients. The formulation is incompatible with hydrogen peroxide-based wound cleansers; residual peroxide above 0.3% in the wound bed can oxidize the hydrophilic emulsifier in RS-800, yielding a separated, brown-tinted ointment within 4–6 h at 32 °C. The controlled addition ratio of RS-800 above 85 wt% creates an overly occlusive film with WVTR below 200 g/m²/24 h, which may macerate peri-wound skin; below 55 wt%, the matrix loses its continuous-phase integrity and water separates during 24 h storage at 25 °C unless a secondary emulsifier is added at 2–5 wt%. Published data for RS-800-specific WVTR values in non-petrolatum systems is limited; pilot batches should be evaluated per ASTM E96/E96M-22 and ISO 10993-1:2018 before master manufacturing records are approved.

When Aqueous Phase Heating Is Eliminated from Cosmetic Cream Production

Cosmetic manufacturing lines using cold-process emulsification adopt RS-800 High Stable Hydrophilic Ointment as a pre-formed hydrophilic phase to eliminate the energy cost and thermal degradation risk associated with heating aqueous and lipid phases to 70–80 °C. The base is added at 40–75 wt% into a 200 L vacuum planetary mixer, accompanied by 15–30 wt% of a 1:1 glycerin-water premix, 3–8 wt% caprylic/capric triglyceride, 1–3 wt% cetearyl alcohol, 0.3–1.0 wt% xanthan gum, and 0.5–1.5 wt% phenoxyethanol/ethylhexylglycerin as the preservative system permitted by Annex V of EU Cosmetics Regulation (EC) No 1223/2009 and 21 CFR 330.1 for OTC skin protectants where applicable. Compliance for the cosmetic finished goods requires ISO 22716:2007 good manufacturing practices, microbiological limits per ISO 17516:2014, and microbial enumeration per ISO 21148:2017 with limits of ≤10³ CFU/g total aerobic count and ≤10² CFU/g yeast and mold. The mixing sequence adds the RS-800 base to the planetary mixer first at 25 °C, followed by slow injection of the glycerin-water premix at 150–200 mL/min through a spray lance to avoid localized coalescence; the orbital speed is maintained at 25–50 rpm and the high-speed disperser runs at 1,000–1,500 rpm for 5–8 min. Xanthan gum is pre-slurried in 2–3 parts of caprylic/capric triglyceride and added after the aqueous premix, while cetearyl alcohol is added last at a slow screw feed of 0.5 kg/min to prevent lump formation. The resulting cream is deaerated at -0.09 MPa for 10–15 min and filled into 50–200 mL polypropylene jars or 30–75 mL PE tubes. Terminal finished product types include cold creams, hand creams, and lotion bars. The primary limitation is that cold-process creams made with RS-800 exhibit a narrower viscosity tolerance than hot-process emulsions; the final viscosity at 25 °C measured per ASTM D2196-20 with a T-bar spindle at 5 rpm should remain between 25,000–70,000 mPa·s, and excursions above 70,000 mPa·s indicate over-hydration of the xanthan gum network that cannot be reversed without adding 1–2 wt% propanediol. Incompatibility with cationic surfactants above 0.5 wt% such as cetrimonium chloride can produce visible flocculation within 2 h; the process control requires a 50 g bench-scale compatibility check before adding cationic conditioning agents.